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a b s t r a c t
AK2 is an adenylate phosphotransferase that localizes at the intermembrane spaces of the mitochondria,
and its mutations cause a severe combined immunodeﬁciency with neutrophil maturation arrest named
reticular dysgenesis (RD). Although the dysfunction of hematopoietic stem cells (HSCs) has been
implicated, earlier developmental events that affect the fate of HSCs and/or hematopoietic progenitors
have not been reported. Here, we used RD-patient-derived induced pluripotent stem cells (iPSCs) as a
model of AK2-deﬁcient human cells. Hematopoietic differentiation from RD-iPSCs was profoundly
impaired. RD-iPSC-derived hemoangiogenic progenitor cells (HAPCs) showed decreased ATP distribution
in the nucleus and altered global transcriptional proﬁles. Thus, AK2 has a stage-speciﬁc role in main-
taining the ATP supply to the nucleus during hematopoietic differentiation, which affects the tran-
scriptional proﬁles necessary for controlling the fate of multipotential HAPCs. Our data suggest that
maintaining the appropriate energy level of each organelle by the intracellular redistribution of ATP is
important for controlling the fate of progenitor cells.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Reticular dysgenesis (RD, OMIM: 267500) is an extremely rare
autosomal recessive disorder caused by hypofunctional mutations
in adenylate kinase 2 (AK2) [1,2]. RD patients suffer from severe
combined immunodeﬁciency (SCID) with profound T lymphopenia
and neutrophil maturation arrest [3]. Although the recapitulation
of hematopoietic manifestations has been reported in vitro in
cultured AK2 knockdown cells [1,4] and patient-derived induced
pluripotent cells (iPSCs) [5] and in vivo in a zebraﬁsh model [2,5],
the underlying pathophysiology linking the function of AK2 to the
fate of hematopoietic progenitors has not been fully clariﬁed.
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Additionally, in those previous models, although the dysfunction of
hematopoietic stem cells (HSCs) has been implicated, earlier
developmental events that affect the fate of the HSCs and/or he-
matopoietic progenitors have not been reported.
AK2 is an isoenzyme of adenylate kinases (AKs, EC 2.7.4.3). The
phosphotransfer network of AKs is an important intracellular sys-
tem that contributes to energy redistribution among distinct sub-
cellular compartments [6]. AKs are evolutionally conserved
enzymes that catalyze the reversible adenine nucleotide phos-
phoryl transfer of adenine nucleotides through the reaction
ATPþAMP4 2ADP [6]. AK2 localizes to the intermembrane spaces
of mitochondria and is involved in various cellular biological
functions [4,5,7e9]. The unique subcellular localization suggests a
distinct role of AK2 on energy communication between intra- and
extra-mitochondrial compartments. However, the impact of AK2 on
the intracellular ATP concentration in each subcellular compart-
ment has not been directly evaluated.
Adenosine triphosphate (ATP) is an essential energy currency in
cells. ATP is mainly produced in the mitochondria and cytosol, and
is consumed by various organelles including the nucleus. The main
sites of ATP production transition dynamically during differentia-
tion [10]. Additionally, alterations in the intracellular energy
metabolism in stem/progenitor cells affect the fate of progenies. For
example, cellular bioenergetic homeostasis has been linked to the
fate of HSCs [11,12]. Cytosolic energy sensors and glycolytic en-
zymes play critical roles in maintaining and regulating the stem-
ness of HSCs [13,14]. The fate control of hematopoietic progenitor
cells is also affected by the altered metabolism [15]. However, since
current methods for evaluating the transition of the metabolic
status during differentiation are mainly whole-cell based, whether
metabolic miscommunication among subcellular compartments
affects the fate of progenitor cells remains to be elucidated. To
address this possibility, tracing the distribution of intracellular ATP
during hematopoietic differentiation is necessary.
In the present study, we used RD-patient-derived iPSCs [16] as a
model for understanding the underlying mechanism linking AK2
function and hematopoietic differentiation. We focused on human
AK2, because the embryonic lethality observed in animal models of
homozygous AK2 deletion [17,18] (including our unpublished
observation in mice) indicates the existence of unique redundant
AK2 pathways in humans [8]. By using these models, we found that
the differentiation propensity was impaired in early-stage he-
matopoietic progenitors derived from AK2 mutant iPSCs.
2. Materials and methods
2.1. Primers and antibodies
The primers and antibodies used in this study are listed in
Supplementary Tables 3 and 4, respectively.
2.2. Ethical matters
This study was approved by the Ethics Committee of Kyoto
University, and written informed consent was obtained from the
patients' guardians in accordance with the Declaration of Helsinki.
Pretransplant bone marrow stromal cells were obtained from two
independent RD patients (RD1, CIRA00068; and RD2, CIRA00067).
2.3. Establishment of RD-iPSCs
Bone marrow stromal cells were reprogrammed towards iPSCs
using a pseudotyped retroviral transduction protocol with six fac-
tors (OCT4, SOX2, KLF4, LMYC, LIN28 and NANOG) or a combination
of episomal plasmid vectors encoding seven factors (OCT4, SOX2,
KLF4, LMYC, LIN28, EBNA1 and p53 carboxy-terminal dominant-
negative fragment). pMXs retrovirus vectors encoding each factor
together with pMG2.G (Addgene, 12259) were introduced into the
Platinum-GP packaging cell line (Cell Biolabs, Inc.). The viral su-
pernatant was concentrated with PEG-it Virus Precipitation Solu-
tion (System Biosciences). Transduction of the retroviral vectors
and the subsequent harvesting of PSC-like colonies were performed
as previously described [16]. Episomal plasmid vectors encoding
each factor were transduced into bone marrow stromal cells by
electroporation [19].
2.4. Hematopoietic cell differentiation from PSCs
The hematopoietic cell differentiation protocol was modiﬁed
from a previously described serum and feeder-free monolayer
system [20,21].
2.5. T lymphocyte differentiation from PSCs
T-lineage cells were obtained from RD-iPSCs or control T cell-
derived iPSCs after coculturing with C3H10T1/2 and OP9-DL1
cells, as previously described [22].
2.6. FRET imaging
ATeam1.03s with and without a mitochondrial or nuclear tar-
geting signal were cloned into a piggyBac vector and transfected
into each PSC. PSCs were cultured on a iMatrix 511 (nippi)-coated
9.5 mm multi-well glass-bottom dish (Matsunami), and adherent
CD34 þ KDR þ HAPCs were sorted using FACS, suspended in he-
matopoietic differentiation medium and transferred onto a multi-
well glass bottom dish at a concentration of 1e2  105 cells. After
overnight incubation at 37 C, PSCs and HAPCs were imaged under
identical gain and exposure settings using a FV1000 confocal mi-
croscope with high sensitivity GaAsP detector (Olympus). An image
analysis was performed using Fiji software. Following noise
reduction and background subtraction, the YFP/CFP emission ratio
was calculated from the YFP and CFP intensity obtained from the
same region of the cells.
2.7. Gene expression data
RNA probes were hybridized to SurePrint G3 Human GE 8 60K
Microarrays (Agilent Technologies) according to themanufacturer's
protocols. The microarrays were scanned, and the data were
analyzed using the Bioconductor package limma. The complete
dataset for this analysis is available at the NCBI Gene Expression
Omnibus using accession no. GSE76761.
2.8. Statistical analysis
All statistical analyses were performed using Microsoft Excel,
Python 2.7 and R software programs. A description of each analysis
is available in the Methods, Supplementary Figures and associated
legends.
3. Results
3.1. Generation and evaluation of RD-iPSCs
We obtained bone marrow stromal cells from two RD patients
carrying compound heterozygousmutations in AK2 (patients RD1 and
RD2, Fig. 1A) and introduced reprogramming factors. We have ob-
tained multiple clones to exclude any clonal artifacts (Supplementary
Fig. 1A, Supplementary Table 1A). AK2-supplemented (AK2(þ)) iPSC
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clones from patient-derived cells were used as controls for AK2-
deﬁcient (AK2(-)) iPSC clones. We ﬁnally obtained multiple iPSC
clones from both patients and used 3 AK2(-) and 3 AK2(þ) iPSC clones
fromRD1 and 3 AK2(-) and 2AK2(þ) iPSC clones fromRD2 to evaluate
hematopoietic differentiation capacity (Supplementary Table 1A).
Both AK2(-) and AK2(þ) clones were morphologically comparable
to human embryonic stem cells (ESCs), expressed pluripotency-
associated surface markers (Fig. 1B, Supplementary Table 1A) and
exhibited a normal karyotype (Supplementary Fig.1B, Supplementary
Table 1A). Each established iPSC clone maintained parental AK2 mu-
tations (Supplementary Fig. 1C, Supplementary Table 1A). The exog-
enously introduced reprogramming factors were efﬁciently silenced
(Supplementary Fig. 1D), while PSCespeciﬁc transcription factors
were well expressed in all patient-derived iPSCs (OCT3/4, SOX2,
NANOG, LIN28 and REX1, Supplementary Fig. 1D, Supplementary
Table 1A). All AK2(-) and AK2(þ) iPSCs successfully differentiated
into three germ layers in a teratoma formation assay (Fig. 1C, sum-
marized in Supplementary Table 1A). Exogenous AK2 was efﬁciently
expressed in AK2(þ) iPSC clones (Fig. 1D, Supplementary Figs. 1E and
1F). The promotor regions of OCT3/4 and NANOG were effectively
demethylated in iPSCs (Supplementary Table 1). We conﬁrmed that
exogenously expressed Flag-tagged AK2 was located in the mito-
chondria (Supplementary Fig. 1G). The AK2 enzymatic activity was
profoundly impaired in AK2(-) iPSCs and efﬁciently recovered by
complementation of AK2 in AK2(þ) iPSCs (Fig. 1E and Supplementary
Fig. 1H). Overall, we successfully established disease-speciﬁc iPSCs
from RD patients and AK2-supplemented isogenic counterparts, and
the basic characteristics of iPSCs such as pluripotencywas comparable
between AK2(-) and AK2(þ) clones.
3.2. Defective hematopoietic differentiation in RD-iPSCs
In order to evaluate whether the in vivo phenotype of RD is
recapitulated, we next differentiated RD-iPSCs into hematopoietic
lineages using a step-wise protocol that produces functional
erythroid and myeloid lineages in vitro [20,21]. When differenti-
ated into myeloid lineages, the AK2(-) clones exhibited a sig-
nificant defect in the maturation of neutrophils, which was
completely rescued by the supplementation of wild-type AK2
(Fig. 2A and B). This ﬁnding of neutrophil maturation arrest is
consistent with the pathology of the patient's bone marrow
(Fig. 2A). The maturation defect of neutrophils was observed over
longer time courses (Supplementary Fig. 2A), indicating that the
defect does not reﬂect a delay of maturation, but rather an inability
to produce mature neutrophils. This in vitro phenotype was
reproducibly recapitulated in multiple iPSC clones from both RD1
and RD2 patients (Supplementary Fig. 2B).
Since it remains unknown at which stage T-lymphocyte differ-
entiation is impaired in RD patients, we next differentiated RD-
iPSCs to T-lymphocyte lineage using a protocol that can derive
Fig. 1. Generation and characterization of RD-iPSCs. A, Description of the two RD patients (RD1 and RD2). B, Morphology and expression of PSC markers. Scale bars, 100 mm. C,
Teratomas derived from RD-iPSCs. Scale bars, 100 mm. D, The expression of total (endogenous plus transgenic) AK2 in PSCs. Data represent the mean ± SEM (n ¼ 3 independent
experiments; *, p < 0.05; **, p < 0.01; Student's t-test). E, The enzymatic activity of AK2 in PSCs. Data represent the mean ± SEM (n ¼ 3 independent experiments; *, p < 0.05; **,
p < 0.01; Student's t-test).
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functional T cells in vitro [22]. While CD7þCD5 pro T1 cells were
maintained, CD7þCD5þ pro T2 cells [23] were deﬁcient in AK2(-)
clones (Fig. 2C, Supplementary Fig. 2C), indicating that the initial
commitment to the CD7þCD5þ pro T2 stage is impaired in the T-
lymphopoiesis of RD patients. Overall, the differentiation of mature
neutrophils and T-lymphocytes was severely impaired, which is
consistent with the in vivo phenotype of RD patients.
3.3. Defective hematopoietic output from RD hemoangiogenic
progenitors
To examine which progenitors were responsible for the he-
matopoietic defect, we next evaluated the quantity and quality of
earlier hematopoietic progenitors. We therefore compared the
frequency of CD34 þ KDR þ HAPCs at day 6 and CD34þCD43þ
earlyMPCs at day 9. As shown in Fig. 2D and E, while the fraction of
CD34 þ KDR þ HAPCs was increased in AK2(-) clones, the
CD34þCD43þ early MPCs fraction was decreased in AK2(-) clones.
Apoptotic cells were not increased in either CD34 þ KDR þ HAPCs
or CD34þCD43þ early MPCs (Supplementary Fig. 2D. Therefore,
the output of CD34 þ KDR þ HAPCs seemed impaired in RD pa-
tients. In accordance with this hypothesis, the clonogenicity of
puriﬁed CD34þKDRþ cells in the AK2(-) clones was almost
completely defective (Fig. 2F and Supplementary Fig. 2E). Taken
together, the earliest impairment of the differentiation propensity
of AK2(-) iPSCs to hematopoietic lineage was found at the stage of
CD34 þ KDR þ HAPCs.
3.4. Intracellular ATP redistribution is impaired in AK2(-)
hematopoietic progenitors
The most important putative role of AK2 is to regulate cellular
adenine nucleotides [17], suggesting AK2 is critical for maintaining
ATP levels in speciﬁc subcellular components. Since the above data
indicate that AK2 plays a critical role in mitochondrial homeostasis
in a stage-speciﬁc manner, we next evaluated whether the intra-
cellular redistribution of ATP is affected in RD patients. We ﬁrst
evaluated the total concentration of intracellular metabolites using
capillary electrophoresis-time-of-ﬂight mass spectrometry (CE-
TOFMS) metabolome analysis. At day 6, the loss of AK2 did not
reduce the intracellular ATP concentration of differentiated cells
(Supplementary Fig. 3A). The intracellular balance of adenine
nucleotide, as indicated by the energy change, was not different at
the whole cell level (Supplementary Fig. 3B). We next introduced
ATeam, a ﬂuorescence resonance energy transfer (FRET)-based
genetically encoded indicator of ATP, into iPSCs [24]. The ﬂuores-
cence of ATeam is invariant at the physiological level of pH ﬂuc-
tuation [24]. In iPSCs, the intracellular distribution of ATP was not
dependent on the status of AK2 (Fig. 3A). However, when differ-
entiated into HAPCs, the level of ATP was consistently elevated in
Fig. 2. Defective hematopoietic differentiation in RD-iPSCs. A, MayeGiemsa staining of hematopoietic cells obtained from PSCs (day 22) and patient RD1's bone marrow. Scale bar,
50 mm. B,Morphological classiﬁcation of PSC-derived neutrophils (day 22). Data represent the mean ± SEM (n ¼ 3 independent experiments; *, p < 0.05; **, p < 0.01; ***, p < 0.001;
Student's t-test). C, Representative contour plots of the ﬂow cytometry analysis of T-lymphocyte differentiation (day 35). D-E, Analysis of early hematopoietic progenitors. The cell
number indicates the absolute number of CD34 þ KDR þ HAPCs at day 6 (D) or CD34 þCD43 þ early MPCs at day 9 (E) obtained from 5 undifferentiated ESC/iPSC colonies 500 mm in
diameter. Data represent the mean ± SEM (n ¼ 3 independent experiments; *, p < 0.05; Student's t-test). F, Clonogenic assay of CD34 þ KDR þ HAPCs. Data represent the
mean ± SEM (n ¼ 3 independent experiments; *, p < 0.05; **, p < 0.01; Student's t-test).
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the mitochondria and decreased in the nuclei of AK2(-) clones
(Fig. 3BeD). The cytosolic ATP level remained comparable between
AK2(-) and AK2(þ) clones (Fig. 3BeD). Overall, these data provide
direct evidence that AK2 affects the intracellular redistribution of
ATP at a speciﬁc stage of hematopoietic development, which leads
to the retention of ATP in the mitochondria and a relative shortage
of ATP in the nuclei of HAPCs.
3.5. Altered transcriptional proﬁles of RD-HAPCs
Because the control of cell fate in RD-HAPCs was profoundly
impaired and the nuclear ATP concentration decreased during
hematopoiesis in RD-iPSCs, we hypothesized that the relative
shortage of ATP in the nucleus during hematopoietic differentia-
tion alters the transcriptional proﬁles during hematopoietic
development, thereby determining the fate of hematopoietic
progenitor cells (HPCs). To address this issue, we evaluated
whether the transition of the global expression pattern during
hematopoiesis is perturbed in RD-iPSCs. We ﬁrst compared the
expression proﬁles of ESCs, AK2(-) and AK2(þ) clones during four
sequential developmental stages: undifferentiated PSCs, day 6
CD34 þ KDR þ HAPCs, day 13 CD34 þCD45 þ MPCs and day 22
CD13þCD14 neutrophils (Supplementary Fig. 4). A subsequent
statistical analysis extracted 27,413 probes and showed signiﬁcant
changes among the four stages in at least one clone. We next
selected 11,611 probes that showed a similar transition in the
expression pattern between ESC and AK2(þ) clones through
hematopoietic development (Fig. 4A). Among them 6173 probes
(53.2%) displayed a different expression pattern in AK2(-) clones
(Fig. 4B). Interestingly, when common probes that were continu-
ously expressed or continuously suppressed during the differen-
tiation of ESC and AK2(þ) clones (Fig. 4B, consistent pattern) were
selected from the 6173 differentially expressed probes, distinc-
tively expressed probes in the AK2(-) clones were predominantly
observed at the stage of CD34 þ KDR þ HAPCs (77.2% of the 6173
probes). Next, to identify which stagewasmost affected by the loss
of AK2 activity, we investigated the 6173 probes at each differen-
tiation stage (Fig. 4C). Among these probes, 4800 probes (77.8%)
were discriminated in only one developmental stage (Fig. 4C).
Further, among these 4800 probes, 54.8% were concentrated at the
stage of day 6 CD34 þ KDR þ HAPCs (Fig. 4C). On the other hand,
despite the presence of distinct maturation arrest in AK2(-) clones,
the number of differentially expressed probes in myeloid-
committed cells (day 13 and day 22 cells) was relatively small,
emphasizing the signiﬁcance of the global alteration of the tran-
scriptional proﬁles in undifferentiated multipotential progenitors.
Gene ontology (GO) analysis for the stage of CD34 þ KDR þ HAPCs
revealed that genes promoting hematopoietic differentiation were
downregulated among the differentially expressed genes (Fig. 4D
and Supplementary Table 2).
Collectively, these data support the hypothesis that defective
hematopoietic development in RD patients is associated with an
alteration of the transcriptional network in hematopoietic pro-
genitors. Importantly, AK2 has an impact on the transcription
Fig. 3. Intracellular ATP redistribution is impaired in AK2(-) hematopoietic progenitors. A, ATP concentrations in the different cellular compartments in iPSCs. A higher YFP/CFP ratio
indicates a higher ATP concentration. Dots are individual cells pooled from three or four independent experiments. n indicates the number of cells analyzed. The error bars indicate
the 95% conﬁdence interval of the ratios (***, p < 0.001; Mann-Whitney U test). B, Representative YFP/CFP ratio images of CD34 þ KDR þ HAPCs evaluated according to the FRET-
based ATP indicator ATeam. Scale bars, 20 mm. C, ATP concentrations in the different cellular compartments of CD34 þ KDR þ HAPCs. A higher YFP/CFP ratio indicates a higher ATP
concentration. Dots are individual cells pooled from three or four independent experiments. n indicates the number of cells analyzed. The error bars indicate the 95% conﬁdence
interval of the ratios (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; Mann-Whitney U test). D, A heatmap of the ATP distribution among different cellular compartments (C:
cytosol, N: nucleus, M: Mitochondria) in PSCs and CD34 þ KDR þ HAPCs.
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proﬁles of the genes associated with hematopoiesis in a stage-
speciﬁc manner.
4. Discussion
We herein provided the ﬁrst direct evidence that the subcellular
local distribution of ATP is regulated via AK2-dependent phos-
photransfer. Notably, this AK2-dependent redistribution of ATP is
speciﬁc to HAPCs. The loss of AK2 may hamper the transport of ATP
outside the mitochondria, which subsequently leads to elevated
ATP levels in the mitochondrial matrix. Importantly, the AK2-
dependent shortage of nuclear ATP occurs in a developmental
stage-speciﬁc manner, which indicates that AK2-dependent direct
bioenergetic communication between the mitochondria and the
nucleus may exist in HAPCs.
The causative relationship between nuclear ATP levels and
altered transcriptional proﬁles remains to be demonstrated. Cells
alter the epigenome and transcriptome sequentially during
directed differentiation, alterations that demand the continuous
supply of intra-nuclear energy. Nuclear ATP shortage may affect
ATP-dependent chromatin remodeling, the epigenetic landscape
or RNA polymerase II-mediated transcription. Indeed, a role of
ATP-dependent nucleosome remodeling enzymes on hematopoi-
etic differentiation was previously implicated [25]. RNA meta-
bolism may also be affected by the level of ATP [26].
In contrast to most SCID cases caused by defective signaling
pathways necessary for direct differentiation [27], the underlying
pathophysiology of RD seems more complicated. Our study eluci-
dated that AK2 defects provide a signiﬁcant global and local impact
on the metabolic and transcriptional networks in HAPCs. AK2(-)
HAPCs exhibit defective neutrophil and T cell differentiation, a
phenotype also seen in RD patients. Intriguingly, HAPCs and MPCs
were not spontaneously apoptotic in our experiments, consistent
with the ﬁnding that AK2 mediates FADD-dependent apoptosis in
human cells [8] and in contrast to the enhanced apoptosis observed in
patients' primary ﬁbroblasts and T-lymphocytes [2,28]. Additionally,
Fig. 4. Altered transcriptional proﬁles of RD-HAPCs. A, The microarray data analysis process. B, Heatmaps of probes whose expression transitioned similarly in AK2(þ) RD1 and ESCs
and transitioned differently in AK2(-) RD1 during the four sequential developmental stages. C, Extraction of stage speciﬁc probes which differently expressed in AK2(-) clones. D,
Enriched gene ontology (GO) terms in CD34 þ KDR þ HAPCs. The statistically signiﬁcant cutoff is FDR < 5%.
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activated unfolded protein response [7,29,30] may also account for
the defective hematopoiesis.
With the use of iPSC technology, we were able to track in vitro
hematopoiesis in a stepwise manner and to establish isogenic AK2-
supplemented counterparts and genetically-modiﬁed FRET-based
ATP reporter lines. Since conducting a comprehensive analysis of
patient-derived progenitors is not feasible otherwise, iPSC tech-
nology provides an unprecedented opportunity to dissect human
congenital developmental abnormalities.
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